NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
Direct-to-consumer genetic testing company 23andMe is partnering with clinical trial firm TrialSpark to address low recruitment into clinical trials.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The Guardian writes that UK researchers are concerned that a no-deal Brexit would affect their ability to collaborate on cancer trials in the European Union.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.
Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.
The first trial using CRISPR within the human body is to begin this fall to treat a form of blindness.
An analysis finds that though women make up nearly half of individuals participating in research, they are underrepresented in certain studies, according to Quartz.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.